The Gut Microbiota and Graft versus Host Disease (GVHD)
肠道微生物群和移植物抗宿主病 (GVHD)
基本信息
- 批准号:10287495
- 负责人:
- 金额:$ 23.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-11-09 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAllogenicAnimalsAplastic AnemiaBacillusBacteriaBacterial GenesBacteroidaceaeBile AcidsBile Acids and SaltsBile fluidBiochemical PathwayBiological AssayBiological MarkersBiotaBone Marrow TransplantationButyratesCellsCellular Metabolic ProcessCessation of lifeChemicalsChromatographyCommunitiesComplicationCoupledDNADataDevelopmentDiagnosisDiarrheaDietDietary CarbohydratesDiseaseDisease OutcomeEngineeringEngraftmentEnvironmentEnzymesExanthemaFamilyFecesFoodFutureGenesGerm-FreeGlucocorticoidsGoalsHLA AntigensHigh-Throughput Nucleotide SequencingHomologous TransplantationHumanImmuneImmunityImmunologic Deficiency SyndromesImmunosuppressionImmunosuppressive AgentsInflammatory ResponseIntestinesKnowledgeLeadLifeLinkLiverLongitudinal StudiesMalignant NeoplasmsMass Spectrum AnalysisMediatingMetabolicMetabolic PathwayMetabolismMetagenomicsMicrobeMucinsMultiple MyelomaMusOrganOutcomePathologyPatientsPlayPreventionPrevention approachProbioticsProductionProteobacteriaQuality of lifeRecoveryRefractoryResearchRiskRisk AssessmentRoleSeveritiesShotgun SequencingSkinSteroidsSymptomsT-LymphocyteTaxonomyTissuesToxic effectTransplant RecipientsTransplantationUnited StatesVolatile Fatty Acidsbacterial communitybasebile saltschronic graft versus host diseasecohortdisorder controldisorder riskfecal transplantationgene networkgraft vs host diseasegut bacteriagut microbesgut microbiotahematopoietic cell transplantationhuman dataimmunoprophylaxisintestinal epitheliumleukemia/lymphomaliver inflammationmacromoleculemembermetagenomemetagenomic sequencingmicrobialmicrobial communitymicrobiotamortalitynovel strategiesorgan injuryprebioticspreventrRNA Genesrestorationsmall moleculestool sampletherapy designtreatment responsewound healing
项目摘要
Abstract: The Gut Microbiota and Graft-versus-Host Disease
Hematopoietic cell transplantation (HCT) can be lifesaving for the treatment of numerous conditions, including
leukemia, lymphoma, aplastic anemia, multiple myeloma, some immunodeficiencies, and other diseases.
Unfortunately, graft-versus-host disease (GVHD) is a common complication of HCT, affecting up to 50% of
allogeneic transplant recipients, despite human leukocyte antigen (HLA) matching between donor and recipient
and despite use of immunoprophylaxis. GVHD most commonly affects the gut, liver, and skin, producing
diarrhea, liver inflammation, and rashes, with varying stages (degrees) of organ involvement in different
patients. GVHD is thought to arise from immune cells (e.g. T cells) in the graft that recognize host tissues as
foreign and propagate an inflammatory response. It is unclear why some HCT recipients with equivalent HLA
matching develop GVHD while others are spared, and why some patients with GVHD respond to immune
suppression with glucocorticoid treatment while others develop steroid-refractory GVHD with high mortality.
Some murine studies of bone marrow transplantation have shown that germ-free animals are protected from
GHVD, and human studies have suggested that patients with GVHD have a less diverse gut microbiota early
after transplant, pointing to the important role that microbes play in GVHD. This study will investigate which gut
bacterial species or communities are most associated with risk of GVHD in a longitudinal study of HCT
recipients where stool samples are collected weekly for 100 days, then monthly for 9 months, and subjected to
broad-range 16S rRNA gene PCR with high-throughput sequencing for species-level taxonomic identification
of bacteria. Stool samples from these patients will also be assayed for small molecule metabolites produced by
the bacteria-host interaction that may mediate GVHD, such as short chain fatty acids and bile salts. The goal of
this aim is to identify potential chemical effectors of GVHD. Metagenomic sequencing of stool DNA will be used
to assess the functional and metabolic capability of gut bacterial communities to illuminate how particular
bacterial communities produce metabolites linked to GVHD risk, and to identify particular bacterial species or
strains with the metabolic machinery for impacting GVHD risk. Knowledge gained from this study could be
used in the future to design interventions to reduce the risk of GVHD based on targeted manipulation of the gut
microbiota. For example, identification of particular bacterial species or strains linked to protection from GVHD,
and to the production of metabolites that mediate this protection, could lead to the development of probiotics or
engineered bacterial communities for reducing GVHD risk or treating GVHD. Alternatively, enhancing the
production of beneficial metabolites through exogenous administration or use of prebiotics, and blocking the
production of harmful metabolites could emerge as another approach for mitigating GVHD without further
immune suppression in these very compromised patients.
摘要:肠道微生物区系与移植物抗宿主病
造血细胞移植(Hct)可以挽救多种疾病的生命,包括
白血病、淋巴瘤、再生障碍性贫血、多发性骨髓瘤、某些免疫缺陷等疾病。
不幸的是,移植物抗宿主病(GVHD)是HCT的常见并发症,影响多达50%的
异基因移植受者,尽管供者和受者的人类白细胞抗原(HLA)相匹配
尽管使用了免疫预防措施。移植物抗宿主病最常影响肠道、肝脏和皮肤,产生
腹泻、肝脏炎症和皮疹,不同阶段(程度)的器官受累不同
病人。GVHD被认为是移植物中识别宿主组织的免疫细胞(例如T细胞)引起的
外来的,并传播炎症反应。目前尚不清楚为什么一些具有相同人类白细胞抗原的红细胞移植受者
为什么一些GVHD患者会对免疫产生反应?
用糖皮质激素治疗抑制,而其他人发展为激素难治性移植物抗宿主病,死亡率高。
一些小鼠骨髓移植的研究表明,无菌动物可以免受
GHVD和人类研究表明,GVHD患者早期的肠道微生物区系多样性较少
移植后,指出了微生物在移植物抗宿主病中的重要作用。这项研究将调查哪个肠道
在一项关于HCT的纵向研究中,细菌种类或群落与移植物抗宿主病的风险最相关
收件人每周收集粪便样本100天,然后每月收集粪便样本9个月,并接受
广谱16S rRNA基因聚合酶链式反应和高通量测序用于物种水平的分类鉴定
细菌的数量。这些患者的粪便样本也将被检测产生的小分子代谢物
可能介导移植物抗宿主病的细菌-宿主相互作用,如短链脂肪酸和胆盐。的目标是
这一目的是为了确定GVHD的潜在化学效应。将使用粪便DNA的元基因组测序
评估肠道细菌群落的功能和代谢能力,以阐明其特殊性
细菌群落产生与GVHD风险有关的代谢物,并识别特定的细菌物种或
具有影响GVHD风险的代谢机制的菌株。从这项研究中获得的知识可能是
未来用于设计干预措施,以降低GVHD的风险,其基础是对肠道的有针对性的操作
微生物区系。例如,识别与预防GVHD有关的特定细菌物种或菌株,
以及调节这种保护的代谢物的产生,可能导致益生菌或
为降低GVHD风险或治疗GVHD而设计的细菌群落。或者,增强
通过外源给药或使用益生元来产生有益的代谢物,并阻止
有害代谢物的产生可能成为缓解GVHD的另一种方法,而不需要进一步的
免疫抑制在这些严重受损的患者身上。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID Neal FREDRICKS其他文献
DAVID Neal FREDRICKS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID Neal FREDRICKS', 18)}}的其他基金
Fecal Microbiota Transplantation and Fiber for the Treatment of Graft-versus-host Disease After Hematopoietic Cell Transplantation
粪便微生物群移植和纤维治疗造血细胞移植后移植物抗宿主病
- 批准号:
10737446 - 财政年份:2023
- 资助金额:
$ 23.18万 - 项目类别:
ANAEROBE 2022: the 16th Biennial Congress of the Anaerobe Society of the Americas (ASA)
厌氧菌 2022:第 16 届美洲厌氧菌协会 (ASA) 双年度大会
- 批准号:
10464618 - 财政年份:2022
- 资助金额:
$ 23.18万 - 项目类别:
Prospective Epidemiologic Study of Novel Etiologic Agents of Pelvic Inflammatory Disease
盆腔炎新病因的前瞻性流行病学研究
- 批准号:
10668432 - 财政年份:2020
- 资助金额:
$ 23.18万 - 项目类别:
Prospective Epidemiologic Study of Novel Etiologic Agents of Pelvic Inflammatory Disease
盆腔炎新病因的前瞻性流行病学研究
- 批准号:
10220681 - 财政年份:2020
- 资助金额:
$ 23.18万 - 项目类别:
Prospective Epidemiologic Study of Novel Etiologic Agents of Pelvic Inflammatory Disease
盆腔炎新病因的前瞻性流行病学研究
- 批准号:
10471222 - 财政年份:2020
- 资助金额:
$ 23.18万 - 项目类别:
The Gut Microbiota and Graft versus Host Disease (GVHD)
肠道微生物群和移植物抗宿主病 (GVHD)
- 批准号:
10593458 - 财政年份:2017
- 资助金额:
$ 23.18万 - 项目类别:
The Gut Microbiota and Graft versus Host Disease (GVHD)
肠道微生物群和移植物抗宿主病 (GVHD)
- 批准号:
10053303 - 财政年份:2017
- 资助金额:
$ 23.18万 - 项目类别:
Male urethritis: Novel etiologies and natural history
男性尿道炎:新的病因和自然史
- 批准号:
8672151 - 财政年份:2014
- 资助金额:
$ 23.18万 - 项目类别:
Male urethritis: Novel etiologies and natural history
男性尿道炎:新的病因和自然史
- 批准号:
9001246 - 财政年份:2014
- 资助金额:
$ 23.18万 - 项目类别:
Male urethritis: Novel etiologies and natural history
男性尿道炎:新的病因和自然史
- 批准号:
8815259 - 财政年份:2014
- 资助金额:
$ 23.18万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 23.18万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 23.18万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 23.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 23.18万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 23.18万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 23.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 23.18万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 23.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 23.18万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 23.18万 - 项目类别:
Grant-in-Aid for Scientific Research (B)














{{item.name}}会员




